Wells Fargo upgraded Regulus (RGLS) to Overweight from Equal Weight with a price target of $6, up from $3.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS:
- Regulus Announces Positive Phase 1b Study Results
- Regulus’ farabursen shows efficacy in Phase 1b kidney disease trial
- Promising Developments and Strategic Positioning Drive Buy Rating for Regulus Therapeutics
- Regulus Therapeutics Reports Positive Trial Results and Financials
- Buy Rating for Regulus Based on Promising Phase 1b Results and Strong Financial Position